Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2606053 | 0.83 | ALDH1A1 (0.62) | ALDH1A1NPC1KDM4EMEN1KMT2A | |
| SCHEMBL2687834 | 0.82 | GNAI3 (0.53) | ALDH1A1NPC1KDM4EJAK1ITGB3 | |
| SCHEMBL21429965 | 0.82 | ALDH1A1 (0.41) | ALDH1A1NPC1KDM4EJAK1ITGB3 | |
| SCHEMBL4630504 | 0.80 | ATM (0.50) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11948185 | 0.80 | ATM (0.44) | ALDH1A1NPC1KDM4EITGB3ITGA2B | |
| SCHEMBL4578079 | 0.80 | ITGB3 (0.43) | ALDH1A1NPC1KDM4EJAK1ITGB3 | |
| SCHEMBL5606075 | 0.80 | L3MBTL1 (0.51) | ALDH1A1NPC1KDM4EITGB3ITGA2B | |
| SCHEMBL8430100 | 0.80 | ITGB3 (0.43) | ALDH1A1NPC1KDM4EJAK1ITGB3 | |
| SCHEMBL4578083 | 0.80 | ITGB3 (0.43) | ALDH1A1NPC1KDM4EJAK1ITGB3 | |
| SCHEMBL13629807 | 0.80 | ALDH1A1 (0.40) | ALDH1A1NPC1KDM4EITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060221-A1 | METHOD FOR PRODUCING NONHUMAN PRIMATE ANIMAL MODEL OF CEREBRAL INFARCTION AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CEREBRAL INFARCTION | ASTELLAS PHARMA INC. (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4660189-A1 | CARBAMOYL LIPID OR UREA LIPID EACH HAVING CYCLIC AMINE, LIPID NANOPARTICLES CONTAINING SAME, AND PHARMACEUTICAL COMPOSITION | Astellas Pharma Inc. (JP) | 2025-12-10 | — | — | EP | disclosed |
| EP-4548757-A1 | METHOD FOR PRODUCING NON-HUMAN PRIMATE MODEL OF CEREBRAL INFARCTION AND PHARMACEUTICAL COMPOSITION FOR TREATING CEREBRAL INFARCTION | Astellas Pharma, Inc. (JP) | 2025-05-07 | — | — | EP | disclosed |
| CN-119451569-A | Preparation method of non-human primate model for cerebral infarction and pharmaceutical composition for cerebral infarction treatment | 安斯泰来制药株式会社 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024162304-A1 | CARBAMOYL LIPID OR UREA LIPID EACH HAVING CYCLIC AMINE, LIPID NANOPARTICLES CONTAINING SAME, AND PHARMACEUTICAL COMPOSITION | アステラス製薬株式会社 | 2024-08-08 | — | — | WO | disclosed |
| WO-2024005124-A1 | METHOD FOR PRODUCING NON-HUMAN PRIMATE MODEL OF CEREBRAL INFARCTION AND PHARMACEUTICAL COMPOSITION FOR TREATING CEREBRAL INFARCTION | アステラス製薬株式会社 | 2024-01-04 | — | — | WO | disclosed |
| EP-3464268-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2020-03-11 | — | — | EP | disclosed |
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| EP-1664028-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026151-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060221-A1 | METHOD FOR PRODUCING NONHUMAN PRIMATE ANIMAL MODEL OF CEREBRAL INFARCTION AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CEREBRAL INFARCTION | FABP7, NES, VEGFA | ALDH1A1 2019/4885NPC1 152/4885KDM4E 4860/4885 |
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ABL1, ERBB2, LCK | ALDH1A1 2485/4885NPC1 4497/4885KDM4E 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.